24 February 2015
The PROUD study today reported that PrEP reduced the
risk of HIV infection by 86% for gay and other men who have sex
with men when delivered in sexual health clinics in
The PROUD study measured the effectiveness of
daily PrEP for gay and other men who have sex with men in
England. The results released at the Conference on
Retroviruses and Opportunistic Infections today indicate that PrEP
is highly protective for this group, reducing the risk of infection
by 86%. The researchers concluded that PrEP offers a major
opportunity to curb new HIV infections in men who have sex with men
in the UK.
The PROUD Study
Examining the impact on gay men of using Pre-Exposure
What is PrEP?
PrEP (Pre-Exposure Prophylaxis) is a new way to reduce
the risk of getting HIV. It involves HIV negative people taking a
daily tablet that contains drugs commonly used to treat
PROUD is a two-year study to recruit volunteers across England,
who will be placed at random into one of two groups. One group will
use PrEP from the start of the study, and the other group will
receive PrEP after 12 months.
Truvada (which contains tenofovir and emtricitabine, also called
FTC) is used in this study. Truvada is already widely used and any
side effects are usually mild.
Previous studies with gay men found that using PrEP almost
halved HIV infections – and there were even fewer infections
amongst men who took their pill every day.